JPMorgan Chase & Co. set a $34.00 target price on Juno Therapeutics Inc (NASDAQ:JUNO) in a report issued on Thursday morning. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. Vetr downgraded shares of Juno Therapeutics from a strong-buy rating to a buy rating and set a $38.02 price objective on the stock. in a report on Monday, August 22nd. FBR & Co set a $61.00 target price on Juno Therapeutics and gave the company a buy rating in a research report on Friday, August 5th. Maxim Group dropped their target price on Juno Therapeutics from $80.00 to $50.00 and set a buy rating on the stock in a research report on Friday, August 5th. Standpoint Research assumed coverage on Juno Therapeutics in a research report on Thursday, August 25th. They issued a buy rating and a $47.00 target price on the stock. Finally, Zacks Investment Research upgraded Juno Therapeutics from a sell rating to a hold rating in a research report on Tuesday, September 6th. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Juno Therapeutics presently has a consensus rating of Buy and an average price target of $40.40.

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at 21.13 on Thursday. The stock’s market cap is $2.17 billion. Juno Therapeutics has a one year low of $19.41 and a one year high of $57.82. The stock’s 50 day moving average is $27.32 and its 200-day moving average is $32.73.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. The firm had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. During the same quarter in the prior year, the business posted ($0.26) EPS. The firm’s quarterly revenue was up 1200.0% on a year-over-year basis. On average, equities analysts forecast that Juno Therapeutics will post ($2.54) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Analysts Give Juno Therapeutics Inc (JUNO) a $34.00 Price Target” was published by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark law. The correct version of this piece of content can be read at http://www.dailypolitical.com/2016/11/30/jpmorgan-chase-co-analysts-give-juno-therapeutics-inc-juno-a-34-00-price-target.html.

In other news, EVP Robert Azelby sold 12,921 shares of the stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $24.14, for a total transaction of $311,912.94. Following the transaction, the executive vice president now owns 48,640 shares in the company, valued at approximately $1,174,169.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Hans Edgar Bishop sold 84,035 shares of the stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $30.28, for a total value of $2,544,579.80. Following the transaction, the chief executive officer now owns 2,518,537 shares in the company, valued at approximately $76,261,300.36. The disclosure for this sale can be found here.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rockefeller Financial Services Inc. increased its position in Juno Therapeutics by 1,433.2% in the third quarter. Rockefeller Financial Services Inc. now owns 3,465 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,239 shares in the last quarter. Advisor Group Inc. increased its position in Juno Therapeutics by 51.4% in the third quarter. Advisor Group Inc. now owns 3,815 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,296 shares in the last quarter. Panagora Asset Management Inc. increased its position in Juno Therapeutics by 55.0% in the third quarter. Panagora Asset Management Inc. now owns 4,200 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 1,490 shares in the last quarter. Societe Generale purchased a new position in Juno Therapeutics during the second quarter valued at approximately $153,000. Finally, SG Americas Securities LLC purchased a new position in Juno Therapeutics during the second quarter valued at approximately $153,000.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.